|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CXorf40B |
Gene summary for CXORF40B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CXorf40B | Gene ID | 541578 |
| Gene name | endothelium and lymphocyte associated ASCH domain 2 | |
| Gene Alias | CXorf40B | |
| Cytomap | Xq28 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q96DE9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 541578 | CXorf40B | LZE4T | Human | Esophagus | ESCC | 5.94e-07 | 2.08e-01 | 0.0811 |
| 541578 | CXorf40B | LZE5T | Human | Esophagus | ESCC | 1.53e-03 | 1.98e-01 | 0.0514 |
| 541578 | CXorf40B | LZE7T | Human | Esophagus | ESCC | 4.31e-09 | 6.20e-01 | 0.0667 |
| 541578 | CXorf40B | LZE8T | Human | Esophagus | ESCC | 5.00e-05 | 1.91e-01 | 0.067 |
| 541578 | CXorf40B | LZE24T | Human | Esophagus | ESCC | 2.36e-19 | 5.45e-01 | 0.0596 |
| 541578 | CXorf40B | LZE21T | Human | Esophagus | ESCC | 3.59e-02 | 1.29e-01 | 0.0655 |
| 541578 | CXorf40B | LZE6T | Human | Esophagus | ESCC | 4.20e-06 | 1.98e-01 | 0.0845 |
| 541578 | CXorf40B | P1T-E | Human | Esophagus | ESCC | 8.59e-12 | 6.17e-01 | 0.0875 |
| 541578 | CXorf40B | P2T-E | Human | Esophagus | ESCC | 5.26e-25 | 4.59e-01 | 0.1177 |
| 541578 | CXorf40B | P4T-E | Human | Esophagus | ESCC | 2.06e-22 | 4.81e-01 | 0.1323 |
| 541578 | CXorf40B | P5T-E | Human | Esophagus | ESCC | 7.12e-14 | 2.69e-01 | 0.1327 |
| 541578 | CXorf40B | P8T-E | Human | Esophagus | ESCC | 1.20e-12 | 2.30e-01 | 0.0889 |
| 541578 | CXorf40B | P9T-E | Human | Esophagus | ESCC | 2.76e-22 | 5.24e-01 | 0.1131 |
| 541578 | CXorf40B | P10T-E | Human | Esophagus | ESCC | 6.28e-36 | 6.11e-01 | 0.116 |
| 541578 | CXorf40B | P11T-E | Human | Esophagus | ESCC | 2.16e-11 | 5.32e-01 | 0.1426 |
| 541578 | CXorf40B | P12T-E | Human | Esophagus | ESCC | 1.64e-23 | 5.30e-01 | 0.1122 |
| 541578 | CXorf40B | P15T-E | Human | Esophagus | ESCC | 4.77e-18 | 3.62e-01 | 0.1149 |
| 541578 | CXorf40B | P16T-E | Human | Esophagus | ESCC | 1.08e-16 | 2.52e-01 | 0.1153 |
| 541578 | CXorf40B | P19T-E | Human | Esophagus | ESCC | 5.82e-05 | 8.46e-01 | 0.1662 |
| 541578 | CXorf40B | P20T-E | Human | Esophagus | ESCC | 1.40e-16 | 4.00e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CXorf40B | SNV | Missense_Mutation | novel | c.265N>T | p.Ile89Phe | p.I89F | Q96DE9 | protein_coding | deleterious(0) | benign(0.17) | TCGA-B6-A409-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
| CXorf40B | SNV | Missense_Mutation | c.101N>G | p.Gln34Arg | p.Q34R | Q96DE9 | protein_coding | tolerated(0.16) | benign(0.009) | TCGA-D8-A146-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CXorf40B | SNV | Missense_Mutation | c.217A>G | p.Arg73Gly | p.R73G | Q96DE9 | protein_coding | tolerated(0.37) | benign(0) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CXorf40B | SNV | Missense_Mutation | c.218N>A | p.Arg73Lys | p.R73K | Q96DE9 | protein_coding | tolerated(0.81) | benign(0.015) | TCGA-E2-A1LH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| CXorf40B | SNV | Missense_Mutation | c.394N>A | p.Glu132Lys | p.E132K | Q96DE9 | protein_coding | tolerated(0.05) | benign(0.006) | TCGA-EK-A2RC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CXorf40B | SNV | Missense_Mutation | novel | c.230N>C | p.Lys77Thr | p.K77T | Q96DE9 | protein_coding | tolerated(0.06) | benign(0) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CXorf40B | SNV | Missense_Mutation | novel | c.158N>A | p.Cys53Tyr | p.C53Y | Q96DE9 | protein_coding | tolerated(0.11) | benign(0.006) | TCGA-B5-A5OC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
| CXorf40B | SNV | Missense_Mutation | c.259G>C | p.Val87Leu | p.V87L | Q96DE9 | protein_coding | tolerated(0.06) | benign(0.003) | TCGA-D1-A0ZS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CXorf40B | SNV | Missense_Mutation | rs144047890 | c.151N>A | p.Asp51Asn | p.D51N | Q96DE9 | protein_coding | tolerated(0.44) | benign(0.055) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| CXorf40B | SNV | Missense_Mutation | novel | c.130N>A | p.Ala44Thr | p.A44T | Q96DE9 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EO-A22S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |